Diaxonhit Signs a Research Service Agreement With Boehringer Ingelheim Corporation for the Discovery of Novel Epitope Targets in Oncology
9/3/2013 2:27:47 PM
Diaxonhit (Paris:ALEHT) (Alternext: ALEHT) enters into a research service agreement with Boehringer Ingelheim for the discovery and characterization of novel splice variants that have the potential to be therapeutic targets for oncology. Through the agreement Boehringer Ingelheim secures an option to acquire the rights to research, develop and commercialize, any targets identified using Diaxonhit’s patented SpliceArray™ discovery platform, with the aim of adding further to its comprehensive research programme to develop innovative new cancer drugs.
Help employers find you! Check out all the jobs and post your resume.
comments powered by